Albaker Waleed, Al Sheikh Mona, Albakr Aishah, Alkhafaji Dania, Al Besher Eman, Al-Hariri Mohammed
Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Department of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Int J Gen Med. 2021 Nov 23;14:8643-8650. doi: 10.2147/IJGM.S336904. eCollection 2021.
Unmanaged cases of obesity might lead to serious conditions and complications, which impair patients' lives. The aim of this study was to assess the effectiveness and safety of daily 3 mg subcutaneous (s/c) Liraglutide amongst obese non-diabetic patients in Eastern Province, Saudi Arabia.
A retrospective cohort study of obese non-diabetic Saudi patients with obesity managed with s/c Liraglutide 3.0 mg who visited the outpatient clinic in Al Mashfa Hospital, Al Khobar, KSA during 2019-2021. We collected patient data from the electronic reporting system for different parameters. Body weight, hemoglobin A1c %, systolic and diastolic blood pressure mmHg were obtained at baseline and after the intervention.
Records of 258 patients who were using a daily dose of Liraglutide 3.0 mg s/c for at least four months have been reviewed. The body weight loss of patients who used Liraglutide for four months was 8.1±0.8 kg. Moreover, around 204 patients continued for up to six months. Meanwhile, the mean body weight loss was 13 kg. There was a significant reduction of hemoglobin A1c (HbA1c) % by 0.43%. The majority of patients (94.5%) reported satisfaction with the treatment, while adverse events were mainly nausea, vomiting and constipation.
Daily s/c Liraglutide of 3.0 mg is effective in producing significant body weight reduction in obese non-diabetic Saudi patients with tolerable minimal side effects and may provide health benefits in terms of reduced risk of obesity and its related outcomes.
肥胖症若不加以控制，可能会引发严重疾病和并发症，从而影响患者生活。本研究旨在评估每日皮下注射3毫克利拉鲁肽对沙特阿拉伯东部省份肥胖非糖尿病患者的有效性和安全性。
一项回顾性队列研究，研究对象为2019年至2021年期间在沙特阿拉伯胡拜尔市阿尔马什法医院门诊就诊、接受皮下注射3.0毫克利拉鲁肽治疗的肥胖非糖尿病沙特患者。我们从电子报告系统收集了患者不同参数的数据。在基线期和干预后获取体重、糖化血红蛋白百分比、收缩压和舒张压（毫米汞柱）。
对258例每日使用3.0毫克皮下注射利拉鲁肽至少四个月的患者记录进行了回顾。使用利拉鲁肽四个月的患者体重减轻了8.1±0.8千克。此外，约204例患者持续使用长达六个月。同时，平均体重减轻了13千克。糖化血红蛋白（HbA1c）百分比显著降低了0.43%。大多数患者（94.5%）对治疗表示满意，而不良事件主要为恶心、呕吐和便秘。
每日皮下注射3.0毫克利拉鲁肽对肥胖非糖尿病沙特患者有显著的减重效果，副作用轻微且可耐受，可能会降低肥胖及其相关后果的风险，对健康有益。
